HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

01 Jan 2025 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

01 Jan 2025 04:46:43 By Nasdaq GlobeNewswire

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

12 Dec 2024 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

11 Dec 2024 22:00:00 By Nasdaq GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

03 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

28 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

21 Nov 2024 22:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 

20 Nov 2024 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

05 Nov 2024 22:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

31 Oct 2024 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

15 Oct 2024 23:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

24 Sep 2024 02:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

08 Sep 2024 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

29 Aug 2024 23:30:00 By Nasdaq GlobeNewswire

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

21 Aug 2024 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

31 Jul 2024 06:00:01 By Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

03 Jul 2024 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2024 Half-Year Financial Results

26 Jun 2024 03:30:00 By Nasdaq GlobeNewswire

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

24 Jun 2024 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

21 Jun 2024 15:00:00 By Nasdaq GlobeNewswire